Two new members elected to Board of Trustees

Posted date

At a recent meeting of Dana-Farber Cancer Institute Board of Trustees, two new trustees were elected to serve three-year terms.

The new trustees are Levi Garraway, MD, PhD, and Frank H. Laukien, PhD. 

Garraway of Hillsborough, CA, was appointed Chief Medical Officer and Executive Vice President, Head of Global Product Development for Roche and Genentech in October 2019. In August 2020, Garraway became a member of the Genentech Board of Directors.

Prior to joining Roche, Garraway served as Senior Vice President, Oncology Research and Development and Novel Target Research at Eli Lilly and Company. Before that, he had a successful academic career as an Associate Professor of Medicine at the Dana-Farber Cancer Institute, Harvard Medical School, an Institute Member of the Broad Institute, and a Howard Hughes Medical Institute investigator.

Garraway has received numerous awards including the Paul Marks Prize for Cancer Research, the Margaret Foti Award for Leadership and Extraordinary Achievement in Cancer Research from the American Association for Cancer Research, the New Innovator Award from the National Institutes of Health (NIH) and an Outstanding Investigator Award from the National Cancer Institute (NCI). In 2009, he was inducted into the American Society for Clinical Investigation and served as its President from 2015-16. He has been inducted into the Association for American Physicians and he National Academy of Medicine.

Garraway received his Bachelor of Arts from Harvard College and his MD and PhD from Harvard Medical School. He completed his residency in internal medicine at the Massachusetts General Hospital and fellowship training in medical oncology at Dana-Farber Cancer Institute.

Laukien, of North Hampton, NH, is Chairman, President and CEO of Bruker Corporation. He joined Bruker in 1985 as a research scientist and became Bruker US president in 1988. Laukien became CEO of Bruker’s mass spectrometry division in 1997 and took Bruker Daltonics public in 2000. From 1997-2008, he also served as co-CEO of Bruker BioSpin, until its merger into the public Bruker company in 2008.

Since 2022, Laukien also is the founder and executive chairman of Gauss Fusion GmbH.

Laukien is a Visiting Scholar in the Harvard Department of Chemistry & Chemical Biology and in the Harvard Origins of Life Initiative. He is also co-Founder of the Galileo Project together with Prof. Avi Loeb, as well as co-Founder and chairman of Copernicus Space Corporation.

He served on the Dean’s Advisory Committee of the MIT School of Science for many years until 2014, and presently serves on the Visiting Committee for the MIT Department of Chemistry.

Laukien is the author of two books: Active Biological Evolution and Origins & Evolution.

In 2017, Laukien was elected a Senator of acatech, the German Academy of Natural and Technical Sciences.  He serves on the board of directors of the Analytical, Life Science and Diagnostic Association (ALDA), and was previously the Chairman of the ALDA industry association.

Laukien holds a Bachelor of Science in physics from MIT (1984), and a PhD in chemical physics from Harvard University (1988).

Media Contacts

If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email

The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.